Physician profile
Michael N Murphy
NPI 1720081490
$6,295.36
in general payments reported to CMS, 2019-2025
28 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.46 · 2021: $1,592 · 2022: $1,040 · 2023: $239 · 2024: $3,124 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,733 · Food and Beverage: $1,470 · Honoraria: $400 · Education: $16.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,732.76 |
| Food and Beverage | $1,469.62 |
| Honoraria | $400.00 |
| Education | $16.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,860.70 | 2021-2025 | Ellipsys Vascular Access System |
| Merit Medical Systems INC | $799.36 | 2022 | |
| Bard Peripheral Vascular, INC. | $464.11 | 2024 | Fluency Endovascular Stent Graft |
| Ardelyx, INC. | $183.90 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Inari Medical, INC. | $178.95 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mallinckrodt Hospital Products INC. | $153.55 | 2023-2025 | Acthar |
| Mozarc Medical US LLC | $100.73 | 2024 | Chameleon |
| Novartis Pharmaceuticals Corporation | $56.41 | 2023-2024 | |
| Amgen INC. | $50.49 | 2021-2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $48.36 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $36.77 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.26 | 2024 | Jardiance |
| Shield Therapeutics INC | $27.82 | 2025 | |
| Kyowa Kirin, INC. | $27.61 | 2025 | |
| Calliditas Therapeutics US INC. | $27.53 | 2023 | Tarpeyo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $26.00 | 2023 | |
| Nxstage Medical, INC. | $25.78 | 2020 | |
| Olympus America INC. | $23.35 | 2024 | Gastrointestinal Videoscope |
| Fresenius USA Marketing, INC. | $20.42 | 2021 | |
| Aurinia Pharma U.S., INC. | $19.06 | 2024 | Lupkynis |
| Akebia Therapeutics INC | $18.68 | 2020 | |
| Daiichi Sankyo INC. | $18.06 | 2021 | |
| Boston Scientific Corporation | $17.98 | 2023 | Interlock |
| Venturemed Group, INC. | $17.54 | 2025 | Flex Vessel Prep System |
| Opko Pharmaceuticals, LLC | $16.43 | 2023 | Rayaldee |
| Scpharmaceuticals INC. | $16.18 | 2024 | |
| Genentech USA, INC. | $15.69 | 2025 | Gazyva |
| Janssen Pharmaceuticals, INC | $15.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.